{"id":1012583,"date":"2026-10-22T09:47:42","date_gmt":"2026-10-22T13:47:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/"},"modified":"2026-10-22T09:47:42","modified_gmt":"2026-10-22T13:47:42","slug":"lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/","title":{"rendered":"LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">SAN DIEGO, Oct.  22, 2026  (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of <a href=\"http:\/\/www.vizz.com\" rel=\"nofollow\" target=\"_blank\">VIZZ<sup>\u00ae<\/sup><\/a> (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results.<\/p>\n<p align=\"justify\">To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 3074036. The live webcast can be accessed\u00a0<a href=\"https:\/\/edge.media-server.com\/mmc\/p\/misxakpu\" rel=\"nofollow\" target=\"_blank\">here<\/a>\u00a0and on the LENZ Therapeutics website at\u00a0<a href=\"https:\/\/lenz-tx.com\/\" rel=\"nofollow\" target=\"_blank\">www.LENZ-tx.com<\/a>\u00a0in the Investors &amp; Media section. A replay of the webcast will be available on the Company\u2019s website for 30 days following the event.<\/p>\n<p align=\"justify\">\n        <strong>About LENZ Therapeutics<\/strong><br \/>\n        <br \/>LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ<sup>\u00ae<\/sup> (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit <a href=\"http:\/\/www.VIZZ.com\" rel=\"nofollow\" target=\"_blank\">www.VIZZ.com<\/a> and <a href=\"http:\/\/www.LENZ-tx.com\" rel=\"nofollow\" target=\"_blank\">www.LENZ-tx.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Dan Chevallard <br \/>LENZ Therapeutics<br \/><a href=\"mailto:IR@LENZ-Tx.com\" rel=\"nofollow\" target=\"_blank\">IR@LENZ-Tx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDU5MSM3OTA5MjUyIzIyNjM5ODc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Mzk3ZDBiZDQtYmQ2ZS00MGY2LWJkMjktMDYwY2RhMDI1ZjVmLTEyNzU1MzctMjAyNi0xMC0yMi1lbg==\/tiny\/LENZ-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of VIZZ\u00ae (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 3074036. The live webcast can be accessed\u00a0here\u00a0and on the LENZ Therapeutics website at\u00a0www.LENZ-tx.com\u00a0in the Investors &amp; Media section. A replay of the webcast will be available on the Company\u2019s website &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1012583","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of VIZZ\u00ae (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 3074036. The live webcast can be accessed\u00a0here\u00a0and on the LENZ Therapeutics website at\u00a0www.LENZ-tx.com\u00a0in the Investors &amp; Media section. A replay of the webcast will be available on the Company\u2019s website &hellip; Continue reading &quot;LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-22T13:47:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDU5MSM3OTA5MjUyIzIyNjM5ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026\",\"datePublished\":\"2026-10-22T13:47:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/\"},\"wordCount\":226,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDU5MSM3OTA5MjUyIzIyNjM5ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/\",\"name\":\"LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDU5MSM3OTA5MjUyIzIyNjM5ODc=\",\"datePublished\":\"2026-10-22T13:47:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDU5MSM3OTA5MjUyIzIyNjM5ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1MDU5MSM3OTA5MjUyIzIyNjM5ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/","og_locale":"en_US","og_type":"article","og_title":"LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 - Market Newsdesk","og_description":"SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) &#8212; LENZ Therapeutics, Inc. (Nasdaq: LENZ or \u201cLENZ\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on the commercialization of VIZZ\u00ae (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that it will host a webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT to report its third quarter 2026 financial results. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 3074036. The live webcast can be accessed\u00a0here\u00a0and on the LENZ Therapeutics website at\u00a0www.LENZ-tx.com\u00a0in the Investors &amp; Media section. A replay of the webcast will be available on the Company\u2019s website &hellip; Continue reading \"LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-22T13:47:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDU5MSM3OTA5MjUyIzIyNjM5ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026","datePublished":"2026-10-22T13:47:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/"},"wordCount":226,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDU5MSM3OTA5MjUyIzIyNjM5ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/","name":"LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDU5MSM3OTA5MjUyIzIyNjM5ODc=","datePublished":"2026-10-22T13:47:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDU5MSM3OTA5MjUyIzIyNjM5ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1MDU5MSM3OTA5MjUyIzIyNjM5ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lenz-therapeutics-to-report-third-quarter-2026-financial-results-on-october-29-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1012583"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1012583\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1012583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1012583"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1012583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}